Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 1:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 229 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Elderly Immune Senescence Clear all
Recruiting Phase 2 Interventional

Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study

NCT06052826
View directory record Official record
Conditions
B-Cell Non-Hodgkin Lymphoma, Multiple Myeloma
Interventions
Best Practice, Cognitive Intervention, Comprehensive Geriatric Assessment, Nutritional Intervention, Physical Therapy, Questionnaire Administration
Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
60 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
Duarte, California • Irvine, California • Winston-Salem, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 14, 2026, 1:22 PM EDT
Active, not recruiting Phase 2 Interventional

Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma

NCT04765111
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Acalabrutinib, Rituximab
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
65 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 14, 2026, 1:22 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis

NCT03575871
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
PF-04965842 100 mg, PF-04965842 200 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
28
States / cities
Anaheim, California • Los Alamitos, California • Rolling Hills Estates, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Oct 14, 2026, 1:22 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Pneumococcal Post-Vaccination Titers

NCT02726347
View directory record Official record
Conditions
Smokers, Elderly, Asthma, COPD, Recurrent Infections
Interventions
PPV-23
Biological
Lead sponsor
National Jewish Health
Other
Eligibility
19 Years to 80 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Oct 14, 2026, 1:22 PM EDT
Recruiting Phase 3 Interventional

A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

NCT07222332
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Baricitinib, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
1 Year to 35 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
5
States / cities
Aurora, Colorado • Tallahassee, Florida • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 14, 2026, 1:22 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effect of mTOR Inhibition and Other Metabolism Modulating Interventions on the Elderly

NCT02874924
View directory record Official record
Conditions
Aging
Interventions
Rapamycin, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
70 Years to 95 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Oct 14, 2026, 1:22 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes

NCT05298254
View directory record Official record
Conditions
Herpes Simplex
Interventions
Non-adjuvanted HSV formulation 1, Non-adjuvanted HSV formulation 2, Non-adjuvanted HSV formulation 3, HSV formulation 1 with adjuvant 1, HSV formulation 2 with adjuvant 1, HSV formulation 3 with adjuvant 1, HSV formulation 1 with adjuvant 2, HSV formulation 2 with adjuvant 2, HSV formulation 3 with adjuvant 2, Placebo, HSVTI_F1, HSVTI_F2
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
505 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
6
States / cities
Phoenix, Arizona • Wichita, Kansas • Kansas City, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 14, 2026, 1:22 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Assess the Efficacy and Safety of Daily OM-85 in Young Children With Recurrent Wheezing

NCT05857930
View directory record Official record
Conditions
Recurrent Wheezing, Wheezing Lower Respiratory Illness
Interventions
OM-85, Placebo
Drug
Lead sponsor
OM Pharma SA
Industry
Eligibility
6 Months to 72 Months
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
31
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 14, 2026, 1:22 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years

NCT04762511
View directory record Official record
Conditions
Herpes Simplex
Interventions
Lower dose formulation of HSV vaccine (GSK4108771A), Low dose formulation of HSV vaccine (GSK4108771A), Medium dose formulation of HSV vaccine (GSK4108771A), High dose formulation of HSV vaccine (GSK4108771A), Placebo (saline)
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 40 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
Lenexa, Kansas • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Oct 14, 2026, 1:22 PM EDT
Completed Phase 1 Interventional

A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old

NCT06064929
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Felzartamab
Drug
Lead sponsor
HI-Bio, A Biogen Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
14
States / cities
La Jolla, California • San Francisco, California • Stanford, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 14, 2026, 1:22 PM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis

NCT04921345
View directory record Official record
Conditions
Moderate-to-Severe Atopic Dermatitis
Interventions
Nemolizumab
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
2 Years to 12 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
14
States / cities
Fountain Valley, California • San Diego, California • Vista, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 14, 2026, 1:22 PM EDT
Completed Phase 3 Interventional Results available

Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less Than 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin

NCT00619801
View directory record Official record
Conditions
Allergic Rhinitis, Chronic Urticaria
Interventions
Levocetirizine, Placebo
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
2 Years to 6 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
28
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 14, 2026, 1:22 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)

NCT05144009
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Loncastuximab Tesirine, Rituximab
Drug
Lead sponsor
ADC Therapeutics S.A.
Industry
Eligibility
65 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
29
States / cities
Tucson, Arizona • Little Rock, Arkansas • Aurora, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Oct 14, 2026, 1:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Almonds on Immune Strength and Response to Flu Vaccination in Overweight Older Men and Postmenopausal Women: A Randomized Controlled Study

NCT05031663
View directory record Official record
Conditions
Immune Response, Inflammation
Interventions
Almond group, Control Group
Dietary Supplement
Lead sponsor
Loma Linda University
Other
Eligibility
40 Years to 70 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 14, 2026, 1:22 PM EDT
Recruiting Phase 3 Interventional

A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

NCT06807281
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Abrocitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 11 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
11
States / cities
Birmingham, Alabama • North Little Rock, Arkansas • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 14, 2026, 1:22 PM EDT
Completed Phase 2 Interventional Results available

Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS

NCT02410200
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
dimethyl fumarate
Drug
Lead sponsor
Biogen
Industry
Eligibility
10 Years to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Bernardino, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2017 · Synced Oct 14, 2026, 1:22 PM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma

NCT00193479
View directory record Official record
Conditions
Non-Hodgkins Lymphoma
Interventions
Cyclophosphamide, Mitoxantrone, Vincristine, Prednisone, Rituximab
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
2
States / cities
Fort Myers, Florida • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Oct 14, 2026, 1:22 PM EDT
Completed Not applicable Interventional

Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study

NCT05972577
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aplastic Anemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm, Hodgkin Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Plasma Cell Myeloma
Interventions
Health Promotion and Education, Medical Device Usage and Evaluation, Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
60 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 14, 2026, 1:22 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis

NCT02118792
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
AN2728 Topical Ointment, 2%, Matching vehicle control
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years and older
Enrollment
764 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Henrico, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 14, 2026, 1:22 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of Efficacy of CDZ173 in Patients With APDS/PASLI

NCT02435173
View directory record Official record
Conditions
Common Variable Immunodeficiency (CVID), APDS / PASLI
Interventions
CDZ173, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Oct 14, 2026, 1:22 PM EDT
Completed Not applicable Interventional

Achieving Better Control for Older Adults With Asthma

NCT01979055
View directory record Official record
Conditions
Asthma, Elderly
Interventions
Self-regulation intervention, Telephone follow-up
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
55 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Ann Arbor, Michigan • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 14, 2026, 1:22 PM EDT
Terminated Phase 1 Interventional

Allo CART-19 Protocol

NCT01551043
View directory record Official record
Conditions
Acute Lymphocytic Leukemia
Interventions
CART-19
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 9, 2020 · Synced Oct 14, 2026, 1:22 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults

NCT05966090
View directory record Official record
Conditions
Respiratory Syncytial Viruses, Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 OA investigational vaccine, HZ/su vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
530 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
11
States / cities
Daphne, Alabama • Tempe, Arizona • Corte Madera, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 14, 2026, 1:22 PM EDT
Recruiting Phase 2 Interventional

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

NCT04546399
View directory record Official record
Conditions
Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia
Interventions
3-Dimensional Conformal Radiation Therapy, Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Calaspargase Pegol, Cytarabine, Dexamethasone, Hydrocortisone Sodium Succinate, Lumbar Puncture, Mercaptopurine, Methotrexate, Nivolumab, Pegaspargase, Vincristine Sulfate
Radiation · Drug · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 30 Years
Enrollment
461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
211
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 151 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 14, 2026, 1:22 PM EDT